Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 40
Filtrar
Más filtros

Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Reumatismo ; 74(4)2023 Mar 21.
Artículo en Inglés | MEDLINE | ID: mdl-36942981

RESUMEN

Rheumatic musculoskeletal diseases or RMD [rheumatoid arthritis (RA) and spondyloarthritis (SpA)] are systemic inflammatory diseases for which there are no biomarkers capable of predicting treatments with a higher likelihood of response in naive patients. In addition, the expiration of the anti-TNF blocking drugs' patents has resulted in the availability of anti-TNF biosimilar drugs with the same efficacy and safety than originators but at significantly reduced prices. To guarantee a personalized therapeutic approach to RMD treatment, a board of rheumatologists and stakeholders from the Campania region, Italy, developed a clinically applicable arthritis therapeutic algorithm to guide rheumatologists (DATA project). The general methodology relied on a Delphi technique forecast to produce a set of statements that summarized the experts' consensus. Selected clinical scenarios were discussed in light of the available evidence, and there were two rounds of voting on the therapeutic approaches. Separate discussions were held regarding rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The decision-making factors for each disease were clinical presentation, demographics, and comorbidities. In this paper, we describe a virtuous process between rheumatologists and healthcare system stakeholders that resulted in the development of a shared therapeutic algorithm for RMD patients naive to bDMARDs.


Asunto(s)
Antirreumáticos , Artritis Psoriásica , Artritis Reumatoide , Espondiloartritis , Espondilitis Anquilosante , Humanos , Inhibidores del Factor de Necrosis Tumoral/uso terapéutico , Espondilitis Anquilosante/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Artritis Psoriásica/diagnóstico , Artritis Psoriásica/tratamiento farmacológico , Atención a la Salud , Algoritmos , Antirreumáticos/uso terapéutico
2.
Arch Ital Biol ; 156(4): 171-182, 2018 Dec 31.
Artículo en Inglés | MEDLINE | ID: mdl-30796761

RESUMEN

This work represents a detailed methodological description of automated stereology dedicated to all brainstem catecholamine nuclei. Each tyrosine-hydroxylase-containing nucleus was analyzed to count the following features: i) nuclear volume; ii) neuron number per nucleus; iii) neuron area per each nucleus.A number of reports described catecholamine-containing neurons within brainstem of a variety of animal species. In a recently published work, we reported a simultaneous quantitative analysis of tyrosine hydroxylase-positive neurons in the whole brainstem. Here we report the detailed step by step stereological procedure which allowed to perform a morphometric assessment of each catecholamine nucleus. This protocol provides the method chance to analyze simultaneously various morphological features in the same experimental setting to avoid variability when single nuclei are analyzed in different experiments. This improves the reliability of comparisons between brainstem catecholamine nuclei within the reticular formation to increase our insight about the key functional roles played by these cells in the mammalian brain. In fact, despite being a discrete number of neurons scattered in a small brain area, these cells provide remarkable axonal collateralization which allows the modulation of neuronal activity in the entire CNS. The step by step description of brainstem stereology provided here is reported in order to share these methods and enhance quantitative studies about these fascinating nuclei. At the same time we aim to provide a tool to be used routinely when analyzing the morphology and physiology of brainstem catecholamine cells.


Asunto(s)
Tronco Encefálico , Catecolaminas , Neuronas , Animales , Tronco Encefálico/citología , Catecolaminas/análisis , Ratones , Reproducibilidad de los Resultados
3.
Arch Ital Biol ; 155(1-2): 81-97, 2017 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-28715601

RESUMEN

The cellular prion protein (PrPc) is physiologically expressed within selective brain areas of mammals. Alterations in the secondary structure of this protein lead to scrapie-like prion protein (PrPsc), which precipitates in the cell. PrPsc has been detected in infectious, inherited or sporadic neurodegenerative disorders. Prion protein metabolism is dependent on autophagy and ubiquitin proteasome. Despite not being fully elucidated, the physiological role of prion protein relates to chaperones which rescue cells under stressful conditions.Methamphetamine (METH) is a widely abused drug which produces oxidative stress in various brain areas causing mitochondrial alterations and protein misfolding. These effects produce a compensatory increase of chaperones while clogging cell clearing pathways. In the present study, we explored whether METH administration modifies the amount of PrPc. Since high levels of PrPc when the clearing systems are clogged may lead to its misfolding into PrPsc, we further tested whether METH exposure triggers the appearance of PrPsc. We analysed the effects of METH and dopamine administration in PC12 and striatal cells by using SDS-PAGE Coomassie blue, immune- histochemistry and immune-gold electron microscopy. To analyze whether METH administration produces PrPsc aggregates we used antibodies directed against PrP following exposure to proteinase K or sarkosyl which digest folded PrPc but misfolded PrPsc. We fond that METH triggers PrPsc aggregates in DA-containing cells while METH is not effective in primary striatal neurons which do not produce DA. In the latter cells exogenous DA is needed to trigger PrPsc accumulation similarly to what happens in DA containing cells under the effects of METH. The present findings, while fostering novel molecular mechanisms involving prion proteins, indicate that, cell pathology similar to prion disorders can be mimicked via a DA-dependent mechanism by a drug of abuse.


Asunto(s)
Dopaminérgicos/farmacología , Metanfetamina/farmacología , Neuronas/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Proteínas PrPSc/efectos de los fármacos , Proteínas Priónicas/efectos de los fármacos , Neoplasias de las Glándulas Suprarrenales , Animales , Línea Celular Tumoral , Dopamina/metabolismo , Electroforesis en Gel de Poliacrilamida , Endopeptidasa K/farmacología , Ratones , Microglía/efectos de los fármacos , Neostriado/citología , Neuronas/metabolismo , Feocromocitoma , Proteínas PrPSc/metabolismo , Proteínas Priónicas/metabolismo , Ratas , Sarcosina/análogos & derivados , Sarcosina/farmacología
4.
Biol Sport ; 30(4): 301-9, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24744502

RESUMEN

IN THE PRESENT STUDY WE INVESTIGATED THE EFFECT OF TWO DIFFERENT EXERCISE PROTOCOLS ON FIBRE COMPOSITION AND METABOLISM OF TWO SPECIFIC MUSCLES OF MICE: the quadriceps and the gastrocnemius. Mice were run daily on a motorized treadmill, at a velocity corresponding to 60% or 90% of the maximal running velocity. Blood lactate and body weight were measured during exercise training. We found that at the end of training the body weight significantly increased in high-intensity exercise mice compared to the control group (P=0.0268), whereas it decreased in low-intensity exercise mice compared to controls (P=0.30). In contrast, the food intake was greater in both trained mice compared to controls (P < 0.0001 and P < 0.0001 for low-intensity and high-intensity exercise mice, respectively). These effects were accompanied by a progressive reduction in blood lactate levels at the end of training in both the exercised mice compared with controls (P=0.03 and P < 0.0001 for low-intensity and high-intensity exercise mice, respectively); in particular, blood lactate levels after high-intensity exercise were significantly lower than those measured in low-intensity exercise mice (P=0.0044). Immunoblotting analysis demonstrated that high-intensity exercise training produced a significant increase in the expression of mitochondrial enzymes contained within gastrocnemius and quadriceps muscles. These changes were associated with an increase in the amount of slow fibres in both these muscles of high-intensity exercise mice, as revealed by the counts of slow fibres stained with specific antibodies (P < 0.0001 for the gastrocnemius; P=0.0002 for the quadriceps). Our results demonstrate that high-intensity exercise, in addition to metabolic changes consisting of a decrease in blood lactate and body weight, induces an increase in the mitochondrial enzymes and slow fibres in different skeletal muscles of mice, which indicates an exercise-induced increase in the aerobic metabolism.

5.
Neuroscience ; 149(4): 871-84, 2007 Nov 23.
Artículo en Inglés | MEDLINE | ID: mdl-17959316

RESUMEN

Methamphetamine produces locomotor activation and typical stereotyped motor patterns, which are commonly related with increased catecholamine activity within the basal ganglia, including the dorsal and ventral striatum. Since the cerebellum is critical for movement control, and for learning of motor patterns, we hypothesized that cerebellar catecholamines might be a target of methamphetamine. To test this experimental hypothesis we injected methamphetamine into C57 Black mice at the doses of 5 mg/kg two or three times, 2 h apart. This dosing regimen is known to be toxic for striatal dopamine terminals. However, we found that in the cerebellum, methamphetamine increased the expression of the primary transcript of the tyrosine hydroxylase (TH) gene, followed by an increased expression of the TH protein. Increased TH was localized within Purkinje cells, where methamphetamine increased the number of TH-immunogold particles, and produced a change in the distribution of the enzyme by increasing the cytoplasmic percentage. Increased TH expression was accompanied by a slight increase in noradrenaline content. This effect was highly site-specific for the cortex of posterior vermal lobules, while only slight effects were detectable in the hemispheres. The present data indicate that the cerebellum does represent a target of methamphetamine, which produces specific and fine alterations of the catecholamine system involving synthesis, amount, and compartmentalization of TH as well as increased noradrenaline levels. This may be relevant for motor alterations induced by methamphetamine. In line with this, inherited cerebellar movement disorders in various animal species including humans are associated with increased TH immunoreactivity within intrinsic neurons of the same lobules of the cerebellar cortex.


Asunto(s)
Inhibidores de Captación Adrenérgica/farmacología , Corteza Cerebelosa/efectos de los fármacos , Expresión Génica/efectos de los fármacos , Metanfetamina/farmacología , Norepinefrina/metabolismo , Tirosina 3-Monooxigenasa/genética , Análisis de Varianza , Animales , Corteza Cerebelosa/citología , Corteza Cerebelosa/metabolismo , Corteza Cerebelosa/ultraestructura , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Masculino , Ratones , Ratones Endogámicos C57BL , Microscopía Inmunoelectrónica/métodos , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Factores de Tiempo , Tirosina 3-Monooxigenasa/metabolismo
6.
Brain Res ; 1135(1): 219-29, 2007 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-17222394

RESUMEN

Parkinsonian patients are treated with dopamine replacement therapy (typically, intermittent administration of the dopamine precursor L-DOPA); however, this is associated with the onset of abnormal involuntary movements, which seriously impair the quality of life. The molecular mechanisms underlying abnormal involuntary movements represent an intense field of investigation in the area of neurobiology of disease, although their aetiology remains unclear. Apart from the fine cellular mechanisms, the pathways responsible for the generation of abnormal involuntary movements may involve changes in neurotransmitter systems. A potential candidate is noradrenaline, since a severe loss of this neurotransmitter characterizes Parkinson's disease, and noradrenergic drugs produce a symptomatic relief of L-DOPA-induced dyskinesia. In previous studies we found that pulsatile dopamine release, in the absence of the physiological noradrenaline innervation, produces motor alterations and ultrastructural changes within striatal neurons. In the present study we demonstrate that a unilateral damage to the noradrenaline system anticipates the onset and worsens the severity of L-DOPA-induced contralateral abnormal involuntary movements in hemi-parkinsonian rats. Similarly, ubiquitin-positive striatal ultrastructural changes occur in unilaterally dopamine-depleted, noradrenaline-deficient rats following chronic L-DOPA administration. This study confirms a significant impact of the noradrenergic system in the natural history of Parkinson's disease and extends its role to the behavioural and morphological effects taking place during pulsatile dopamine replacement therapy.


Asunto(s)
Dopaminérgicos , Discinesia Inducida por Medicamentos/etiología , Discinesia Inducida por Medicamentos/patología , Locus Coeruleus/patología , Neuronas/patología , Inhibidores de Captación Adrenérgica/administración & dosificación , Animales , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Desipramina/administración & dosificación , Modelos Animales de Enfermedad , Dopamina/metabolismo , Interacciones Farmacológicas , Lateralidad Funcional , Levodopa/administración & dosificación , Masculino , Neuronas/efectos de los fármacos , Neuronas/ultraestructura , Norepinefrina/metabolismo , Oxidopamina/efectos adversos , Ratas , Ratas Wistar , Prueba de Desempeño de Rotación con Aceleración Constante , Índice de Severidad de la Enfermedad , Tirosina 3-Monooxigenasa/metabolismo
7.
Reumatismo ; 59(3): 240-3, 2007.
Artículo en Italiano | MEDLINE | ID: mdl-17898885

RESUMEN

Renal amyloidosis is a complication of ankylosing spondylitis. A possible pathogenetic role is due to TNF-alpha, with a direct action on glomerular receptors TNFR2 and renal injury, secondary to deposition of amyloid fibrils. The most frequent clinical manifestation is proteinuria or nephrotic syndrome. Etanercept, a soluble receptor of TNF-alpha, binds this circulant cytokine with a progressive improvement of renal function and reduction of deposits of amyloid. Transient leukopenia, observed during ankylosing spondylitis, should not be considered a controindication to the use of Etanercept, but it requires a constant monitoring. The benefit observed in our patient can represent an indication to the use of Etanercept for the management of amyloidosis.


Asunto(s)
Amiloidosis/tratamiento farmacológico , Inmunoglobulina G/uso terapéutico , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Espondilitis Anquilosante/complicaciones , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Anciano , Amiloidosis/diagnóstico , Amiloidosis/etiología , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/uso terapéutico , Quimioterapia Combinada , Etanercept , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Indometacina/administración & dosificación , Indometacina/uso terapéutico , Masculino , Metotrexato/administración & dosificación , Metotrexato/uso terapéutico , Metilprednisolona/administración & dosificación , Metilprednisolona/uso terapéutico , Proteinuria/etiología , Proteína Amiloide A Sérica/análisis , Espondilitis Anquilosante/diagnóstico
8.
Brain Res Bull ; 69(2): 95-100, 2006 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-16533656

RESUMEN

Prion diseases include a group of either sporadic, inherited or infectious disorders characterized by spongiform neurodegeneration and reactive glyosis in several brain regions. Whatever the origin, the neuropathological hallmark of prion diseases is the presence of brain aggregates containing an altered isoform of a cellular protein, named prion protein. Recent findings show the potential toxicity of the normal cellular prion protein, which occurs when its physiological metabolism is altered. In particular, several studies demonstrate that accumulation of the prion protein in the cytosol can be a consequence of an increased amount of misfolded prion proteins, a derangement of the correct protein trafficking or a reduced activity of the ubiquitin-proteasome system. The same effects can be a consequence of a mutation in the gene coding for the prion protein. In all these conditions, one assists to accumulation and self-replication of insoluble prion proteins which leads to a severe disease resembling what observed following typical "prion infections". This article provides an opinion aimed at reconciling the classic Prusiner's theory concerning the "prion concepts" with the present knowledge arising from experimental studies on neurodegenerative disorders, suggesting a few overlapping steps in the pathogenesis of these diseases.


Asunto(s)
Encéfalo/fisiopatología , Enfermedades por Prión/fisiopatología , Priones/metabolismo , Encéfalo/metabolismo , Encéfalo/patología , Transmisión de Enfermedad Infecciosa , Cuerpos de Inclusión/genética , Cuerpos de Inclusión/metabolismo , Cuerpos de Inclusión/patología , Modelos Neurológicos , Enfermedades por Prión/genética , Enfermedades por Prión/metabolismo , Priones/genética , Complejo de la Endopetidasa Proteasomal/genética , Complejo de la Endopetidasa Proteasomal/metabolismo , Pliegue de Proteína , Transporte de Proteínas/genética , Ubiquitina/genética , Ubiquitina/metabolismo
9.
Neuroscience ; 136(1): 43-53, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16203101

RESUMEN

Seizures represent the most common neurological emergency in ecstasy abusers; however, no study addressed whether (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") per se might produce long-lasting alterations in brain excitability related to a pro-convulsant effect. C57 Black mice were treated with three regimens of (+/-) 3,4-methylenedioxymethamphetamine (5mg/kg x 2 for 1, 2 or three consecutive days). Following the last dose of (+/-) 3,4-methylenedioxymethamphetamine, during a time interval of 8 weeks, the following procedures were carried out: 1) cortical electroencephalographic recordings, including power-spectrum analysis; 2) administration of sub-threshold doses of kainate; 3) measurement of regional [(14)C]2-deoxyglucose uptake; 4) monoamine assay. We demonstrate that all mice pre-treated with (+/-) 3,4-methylenedioxymethamphetamine showed long-lasting encephalographic changes with frequencies peaking at 3-4.5 Hz at the power-spectrum analysis. This is concomitant with latent brain hyperexcitability within selected limbic brain regions, as shown by seizure facilitation and long-lasting latent metabolic hyperactivity which can be unraveled by phasic glutamate stimulation. This study sheds new light into the brain targets of (+/-) 3,4-methylenedioxymethamphetamine and discloses the occurrence of (+/-) 3,4-methylenedioxymethamphetamine-induced latent hyperexcitability within limbic areas, while it might provide a model to study in controlled experimental conditions limbic seizures and status epilepticus in C57 Black mice. Persistent changes produced by (+/-) 3,4-methylenedioxymethamphetamine in limbic brain excitability might be responsible for seizures and limbic-related disorders in chronic (+/-) 3,4-methylenedioxymethamphetamine abusers.


Asunto(s)
Encéfalo/metabolismo , Electroencefalografía , Ácido Kaínico , Sistema Límbico/efectos de los fármacos , Sistema Límbico/fisiología , N-Metil-3,4-metilenodioxianfetamina/farmacología , Convulsiones/inducido químicamente , Animales , Monoaminas Biogénicas/metabolismo , Susceptibilidad a Enfermedades , Glucosa/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Convulsiones/fisiopatología
10.
Curr Drug Targets CNS Neurol Disord ; 2(3): 149-52, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12769795

RESUMEN

Lewy bodies (LB) were first described by Lewy in 1912 [1] as neuronal pale eosinophilic inclusions which became a pathological hallmark of Parkinson s disease (PD). In his original study, Lewy defined these inclusions as pale eosinophilic cytoplasmic structures, and studies since then have revealed LB to be ubiquitin-, alpha-synuclein-, and parkin-containing inclusions. This suggests that knowledge of the biochemical steps involved in the genesis of LB might disclose a final common pathway which might be responsible for different types of inherited and sporadic parkinsonism. This would lead to the identification of new therapeutic targets for interfering with disease progression. Although LB were originally described solely in PD, in the last decade these inclusions were described in a spectrum of degenerative disorders ranging from pure movement disorders to dementia. This suggests that common biochemical alterations leading to the formation of intracellular inclusions might underlie various pathological conditions. Consequently, the knowledge of the biochemical steps involved in the formation of neuronal inclusions could represent a key to develop new therapeutic strategies. In recent years it has been possible to develop both in vitro and in vivo neuronal inclusions resembling Lewy bodies. These experimental approaches have ranged from the use of alpha-synuclein transgenic mice to the continuous exposure to a mitochondrial complex I inhibitor. The aim of the present paper is to review briefly, recent advances on Lewy body research to achieve new insight into the etiology of PD and the molecular events leading to neurodegeneration.


Asunto(s)
Evaluación Preclínica de Medicamentos/tendencias , Cuerpos de Lewy/metabolismo , Cuerpos de Lewy/patología , Enfermedades Neurodegenerativas/fisiopatología , Ubiquitinas/metabolismo , Animales , Progresión de la Enfermedad , Activadores de Enzimas/farmacología , Predicción , Humanos , Cuerpos de Lewy/química , Complejos Multienzimáticos/metabolismo , Enfermedades Neurodegenerativas/tratamiento farmacológico , Neuronas/metabolismo , Neuronas/patología , Trastornos Parkinsonianos/fisiopatología , Relación Estructura-Actividad
11.
Psychopharmacology (Berl) ; 173(3-4): 353-63, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-14673567

RESUMEN

RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) is an amphetamine derivative, which is neurotoxic to both serotonin (5HT) and dopamine (DA) nerve terminals. Previous reports, carried out in rodents and non-human primates, demonstrated neurotoxicity to monoamine axon terminals, although no study has analyzed nigral and striatal cell bodies at the sub-cellular level. OBJECTIVE: In this study, we examined intrinsic nigral and striatal cells, and PC12 cell cultures to evaluate whether, in mice, MDMA might affect nigral and striatal cell bodies. METHODS: After administering MDMA, we analyzed effects induced in vivo and in vitro using high-performance liquid chromatography (HPLC) analysis, light- and electron microscopy with immunocytochemistry, and DNA comet assay. RESULTS: We found that MDMA (5 mg/kg x4, 2 h apart), besides a decrease of nigrostriatal DA innervation and 5HT loss, produces neuronal inclusions within nigral and intrinsic striatal neurons consisting of multi-layer ubiquitin-positive whorls extending to the nucleus of the cell. These fine morphological changes are associated with clustering of heat shock protein (HSP)-70 in the nucleus, very close to chromatin filaments. In the same experimental conditions, we could detect oxidation of DNA bases followed by DNA damage. The nature of inclusions was further investigated using PC12 cell cultures. CONCLUSIONS: The present findings lead to re-consideration of the neurotoxic consequences of MDMA administration. In fact, occurrence of ubiquitin-positive neuronal inclusions and DNA damage both in nigral and striatal cells sheds new light into the fine alterations induced by MDMA, also suggesting the involvement of nuclear and cytoplasmic components of the ubiquitin-proteasome pathway in MDMA toxicity.


Asunto(s)
Cuerpo Estriado/efectos de los fármacos , Daño del ADN , N-Metil-3,4-metilenodioxianfetamina/toxicidad , Neuronas/metabolismo , Serotoninérgicos/toxicidad , Sustancia Negra/efectos de los fármacos , Ubiquitina/metabolismo , Animales , Cuerpo Estriado/metabolismo , Cuerpo Estriado/patología , Dopamina/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Neuronas/ultraestructura , Células PC12 , Ratas , Sustancia Negra/metabolismo , Sustancia Negra/patología
12.
Ann N Y Acad Sci ; 965: 381-98, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12105114

RESUMEN

Amphetamine derivatives, such as methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA), act as monoaminergic neurotoxins in the central nervous system. Although there are slight differences in their mechanism of action, these compounds share a final common pathway, which involves dopamine release and oxidative stress. Apart from striatal toxicity involving monoamine axons, no previous report evidenced any alteration at the striatal level concerning postsynaptic sites. Given the potential toxicity for extracellular dopamine at the striatal level, and the hypothesis for neurotoxic effects of dopamine on striatal medium-sized neurons in Huntington's disease, we evaluated at an ultrastructural level the effects of MDMA on intrinsic striatal neurons of the mouse. In this study, administering MDMA, we noted ultrastructural alterations of striatal postsynaptic GABAergic cells consisting of neuronal inclusions shaped as whorls of concentric membranes. These whorls stained for ubiquitin but not for synuclein and represent the first morphologic correlate of striatal postsynaptic effects induced by MDMA.


Asunto(s)
Cuerpo Estriado/ultraestructura , N-Metil-3,4-metilenodioxianfetamina/toxicidad , Sinapsis/ultraestructura , Animales , Bencilaminas/administración & dosificación , Bencilaminas/toxicidad , Monoaminas Biogénicas/metabolismo , Cromatografía Líquida de Alta Presión , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Dopamina/metabolismo , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Endogámicos C57BL , N-Metil-3,4-metilenodioxianfetamina/administración & dosificación , Fosfatidilcolinas/metabolismo , Sinapsis/efectos de los fármacos
13.
Ann N Y Acad Sci ; 1025: 162-70, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15542714

RESUMEN

The monoamine neurotoxin methamphetamine (METH) is commonly used as an experimental model for Parkinson's disease (PD). In fact, METH-induced striatal dopamine (DA) loss is accompanied by damage to striatal nerve endings arising from the substantia nigra. On the other hand, PD is characterized by neuronal inclusions within nigral DA neurons. These inclusions contain alpha-synuclein, ubiquitin, and various components of a metabolic pathway named the ubiquitin-proteasome (UP) system, while mutation of genes coding for various components of the UP system is responsible for inherited forms of PD. In this presentation we demonstrate for the first time the occurrence of neuronal inclusions in vivo in the nigrostriatal system of the mouse following administration of METH. We analyzed, in vivo and in vitro, the shape and the fine structure of these neuronal bodies by using transmission electron microscopy. Immunocytochemical investigation showed that these METH-induced cytosolic inclusions stain for ubiquitin, alpha-synuclein, and UP-related molecules, thus sharing similar components with Lewy bodies occurring in PD, with an emphasis on enzymes belonging to the UP system. In line with this, blockade of this multicatalytic pathway by the selective inhibitor epoxomycin produced cell inclusions with similar features. Moreover, using a multifaceted pharmacological approach, we could demonstrate the need for endogenous DA in order to form neuronal inclusions.


Asunto(s)
Metanfetamina/toxicidad , Complejo de la Endopetidasa Proteasomal/ultraestructura , Inhibidores de Proteasoma , Animales , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/ultraestructura , Ratones , Ratones Endogámicos C57BL , Células PC12 , Ratas , Sustancia Negra/efectos de los fármacos , Sustancia Negra/ultraestructura
14.
Ann N Y Acad Sci ; 1025: 181-8, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15542716

RESUMEN

The psychostimulant 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") is an amphetamine derivative that is widely abused. In previous studies, depending on the animal species, neurotoxicity has been demonstrated for either serotonin (5-HT) or/and dopamine (DA) nerve endings. These studies focused on the basal ganglia circuitry; however, in humans chronic abuse of MDMA often results in neurological symptoms that last after MDMA withdrawal and are not related to the extrapyramidal system such as electroencephalographic (EEG) abnormalities and cognitive impairment. These alterations might be due to the concomitant intake of other illicit compounds, the consequence of MDMA-induced hyperthermia, or to a primary neurotoxicity directed to extrastriatal regions. These observations call for a more in-depth analysis on the potential involvement of brain areas outside the basal ganglia in the toxic effects induced primarily by MDMA. In the present study, we treated C57Black mice chronically (25 days) with daily injections of MDMA (2.5 mg/kg). During treatments, mice were monitored in order to detect behavioral modifications, and epidural electrodes were installed to perform EEG recording. Behavioral data showed a sensitization as measured by locomotor activity, which related to progressive and long-lasting EEG changes and neuronal degeneration within the hippocampus.


Asunto(s)
Electroencefalografía/efectos de los fármacos , Colorantes Fluorescentes/análisis , N-Metil-3,4-metilenodioxianfetamina/administración & dosificación , Animales , Ganglios Basales/química , Ganglios Basales/efectos de los fármacos , Fluoresceínas , Inmunohistoquímica , Locomoción/efectos de los fármacos , Locomoción/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Compuestos Orgánicos
15.
Brain Res ; 861(1): 126-34, 2000 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-10751572

RESUMEN

We recently identified the direct product of dopamine (DA) by monoamine-oxidase (MAO) activity, dihydroxyphenylacetaldehyde (DOPALD) in the trans-striatal dialysate. Based on these findings, in this work, we directly measured the variations in DOPALD levels after various kinds of pharmacological treatment in rat striatal extracellular fluid. Using both reversible and irreversible MAO inhibitors, we found that MAO-A inhibition suppressed, whereas MAO-B inhibition did not modify DOPALD levels in the dialysate. The vesicular DA uptake blocker Ro 4-1284 led to an increase in extracellular DA and DOPALD, whereas the increase in extracellular DA obtained after administration of the plasma membrane DA uptake blocker GBR-12909 occurred without concomitant changes in DOPALD extracellular levels. Microinfusions of DA through the dialysis probe or systemic administration of L-DOPA increased striatal DOPALD to a greater extent compared with other DA metabolites, both in intact and in 6-hydroxydopamine (6-OHDA)-lesioned striatum. This study indicates that the direct product of MAO activity within the rat striatum derives from the activity of the isoenzyme MAO-A. The assay of DOPALD, together with DOPAC, represents a reliable tool to measure directly, in freely moving animals, DA oxidative metabolism. As recent studies have shown that microinfusions of exogenous DOPALD might induce cell death, pharmacological modulation of DOPALD levels might also be relevant for an understanding of the mechanisms involved in DA neurotoxicity.


Asunto(s)
Ácido 3,4-Dihidroxifenilacético/metabolismo , Cuerpo Estriado/efectos de los fármacos , Inhibidores de Captación de Dopamina/farmacología , Dopamina/metabolismo , Ácido Homovanílico/metabolismo , Inhibidores de la Monoaminooxidasa/farmacología , Animales , Cuerpo Estriado/metabolismo , Dopamina/farmacología , Dopaminérgicos/farmacología , Levodopa/farmacología , Masculino , Ratas , Ratas Sprague-Dawley
16.
Eur J Histochem ; 47(4): 359-64, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14706932

RESUMEN

Transforming growth factor-alpha (TGF-alpha) plays an important role in both proliferation and differentiation of mucosal cells at the gastrointestinal level, including stomach, where it is constitutively produced. This study evaluated the immunohistochemical distribution of TGF-alpha within whole gastric mucosa in rats, through the examination of seriate sections. Each stomach was opened along the greater curvature, pinned upon a cork plate, fixed in formalin and cut in 2-mm parallel strips which were sequentially superimposed on a glass slide. Sections were immunostained for TGF-alpha and pictures were taken from three areas: greater and lesser curvature; mucosa lying between the two curvatures. The sections were graded on the basis of the intensity of TGF-alpha staining, which was scored as follows: 0) no staining; 1) weakly positive; 2) intensely positive. The percent number of immunopositive cells and a mean intensity were calculated. Gastric mucosa showed a marked immunopositivity to TGF-alpha, mainly in parietal cells whose cytoplasm displayed moderate to intense staining. Positive cells (and the mean intensity) of total mucosa were 15.7+/-6.1% (1.13+/-0.42). However, they were not uniformly distributed, being 26.3+/-1.9% (1.67+/-0.24) in the mucosa lying between the two curvatures, 12.4+/-2.5% (1.52+/-0.22) along the lesser curvature and 8.3+/-2.1% (0.31+/-0.17) along the greater curvature. These results show that parietal cells of rat gastric mucosa exhibit immunoreactivity to TGF-alpha. Considering the gastroprotective effects of this factor, its non-homogeneous distribution within different areas may be of importance in understanding the lesion pattern of gastric damage after the administration of noxious agents.


Asunto(s)
Técnicas para Inmunoenzimas , Células Parietales Gástricas/metabolismo , Factor de Crecimiento Transformador alfa/metabolismo , Animales , Recuento de Células , Masculino , Microtomía/métodos , Células Parietales Gástricas/citología , Ratas , Ratas Wistar , Estómago/anatomía & histología , Estómago/citología
17.
J Submicrosc Cytol Pathol ; 32(4): 585-90, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11297377

RESUMEN

In previous studies we demonstrated that loud noise exposure induces ultrastructural alterations in the rat myocardium together with an increase in noradrenergic activity and in mitochondrial calcium influx. To verify the causal relationship between myocardial calcium entry and ultrastructural alterations induced by loud noise, in the present study we coupled routine electron microscopy with cytochemistry specifically dedicated to visualize calcium accumulation (revealed as antimonate deposits). We observed that the ultrastructural alterations occurring in both atrium and ventricle after 12 h of noise exposure, were densely packed with antimonate deposits. In particular, enlargements of the sarcoplasmic reticulum and dilution of the mitochondrial matrix, observed during routine electron microscopy, were markedly positive for calcium accumulation when observed by using antimonate. The present data strongly suggest that calcium entry results in accumulation of this ion at myocardial subcellular level. Moreover, the present results joined with previous evidence indicate that calcium accumulation is the final common pathway responsible for noise-induced myocardial morphological alterations.


Asunto(s)
Calcio/metabolismo , Miocardio/metabolismo , Miocardio/ultraestructura , Ruido/efectos adversos , Animales , Histocitoquímica , Masculino , Microscopía Electrónica , Microscopía Electrónica de Rastreo , Mitocondrias Cardíacas/metabolismo , Mitocondrias Cardíacas/ultraestructura , Norepinefrina/metabolismo , Ratas , Ratas Wistar , Retículo Sarcoplasmático/metabolismo , Retículo Sarcoplasmático/ultraestructura
18.
Plant Biol (Stuttg) ; 15(5): 868-81, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23126229

RESUMEN

Cardiospermum L. belongs to the Paullinieae tribe (Sapindaceae) and comprises 16 species. Of these, 12 species are present in South America and all occur in Brazil. Cardiospermum shows the most variable chromosome number of the tribe. Phylogenetic relationships within the genus Cardiospermum, especially with other species of the tribe, are poorly understood. This research focuses on characterisation of the karyotypic features of Cardiospermum using conventional cytogenetic methods, CMA/DAPI chromosome banding and fluorescence in situ hybridisation (FISH). To elucidate the phylogeny of the genus, the nuclear markers ITS1 and ITS2 were sequenced and analysed using maximum parsimony and Bayesian inference. Cardiospermum shows important diversity in basic numbers, with x = 7, 9, 10, 11 and 12. All species studied have metacentric and submetacentric chromosomes, some species have subtelocentric chromosomes, while telocentric chromosomes are absent. The interphase nuclei differentiate the Cardiospermum species into two groups. The CMA(3) /DAPI chromosome banding revealed the presence of an AT-rich terminal region in C. corindum, C. grandiflorum and C. urvilleoides, whereas GC-rich regions were found in C. grandiflorum, C. halicacabum var. halicacabum, C. halicacabum var. microcarpum, C. heringeri and C. integerrimum. FISH revealed syntenic and non-syntenic distribution of the 18-5.8-26S and 5S rDNA. The syntenic distribution always occurred in the short arms of the same chromosome in all of the species. The phylogenetic relationships reveal, in part, the taxonomic arrangement of the genus Cardiospermum.


Asunto(s)
Evolución Biológica , Cromosomas de las Plantas , ADN de Plantas , Cariotipo , Filogenia , Poliploidía , Sapindaceae/genética , Teorema de Bayes , Brasil , Bandeo Cromosómico , ADN Ribosómico/análisis , Evolución Molecular , Hibridación Fluorescente in Situ , Interfase , Cariotipificación , Sapindaceae/clasificación , Sintenía
19.
Histol Histopathol ; 27(6): 753-69, 2012 06.
Artículo en Inglés | MEDLINE | ID: mdl-22473696

RESUMEN

The effects of training are dependent on complex, adaptive changes which are induced by acute physical exercise at different levels. In particular, evidence shows that the hypothalamus-pituitary-adrenocortical axis, as well as the sympatho-adrenomedullary system, is mainly involved in mediating the physiological effects of physical exercise. The aim of the present study was to investigate, through a morphological and biochemical approach, the effects of training on the adrenal gland of mice, following two different protocols consisting of either low- or high-intensity training. Mice were run daily on a motorised treadmill for 8 weeks, at a velocity corresponding to 60% (low-intensity exercise) or 90% (high-intensity exercise) of the maximal running velocity previously determined by an incremental exercise test. We found that physical exercise produced an increase in the adrenal gland size compared with the control (sedentary) mice. The increase was 31.04% for mice that underwent high-intensity exercise and 10.08% for mice that underwent low intensity exercise, and this appeared to be the result of an increase in the area of both the adrenal cortex and adrenal medulla. Morphological analysis of the adrenal cortex showed that both types of exercise produced an increase in cytoplasmic vacuoles in steroidogenic cells, appearing more abundant after high-intensity exercise. No change was found in the reticulate zone. In the adrenal medulla, despite the absence of morphological changes, immunohistochemistry for tyrosine hydroxylase, dopamine ß-hydroxylase and phenyl-ethanolamine-N-methyltransferase demonstrated an increased immunopositivity for these cathecolamine-synthesizing enzymes after intense exercise. These results were confirmed by immunoblot accompanied by densitometric analysis.


Asunto(s)
Glándulas Suprarrenales/metabolismo , Glándulas Suprarrenales/patología , Catecolaminas/metabolismo , Esfuerzo Físico , Adaptación Fisiológica , Glándulas Suprarrenales/ultraestructura , Animales , Western Blotting , Dopamina beta-Hidroxilasa/metabolismo , Inmunohistoquímica , Ácido Láctico/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Microscopía Electrónica de Transmisión , Tamaño de los Órganos , Feniletanolamina N-Metiltransferasa/metabolismo , Carrera , Factores de Tiempo , Tirosina 3-Monooxigenasa/metabolismo , Aumento de Peso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA